ERBB2 and breast cancer: Similarly, ER+/PR+/HER2- breast cancers showed weak or absent cytoplasmic DUSP6 expression (3/10) (Fig 7C), and all (5/5) triple-negative (ER-/PR-/HER2-) breast cancers showed weak cytoplasmic DUSP6 expression (Fig 7D).